Review





Similar Products

95
MedChemExpress nmda receptor antagonist d ap5
Nmda Receptor Antagonist D Ap5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nmda receptor antagonist d ap5/product/MedChemExpress
Average 95 stars, based on 1 article reviews
nmda receptor antagonist d ap5 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

96
Tocris nmda glutamatergic receptor antagonist d ap5
Nmda Glutamatergic Receptor Antagonist D Ap5, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nmda glutamatergic receptor antagonist d ap5/product/Tocris
Average 96 stars, based on 1 article reviews
nmda glutamatergic receptor antagonist d ap5 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

90
Tocris d-ap5 nmda receptor antagonist
D Ap5 Nmda Receptor Antagonist, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/d-ap5 nmda receptor antagonist/product/Tocris
Average 90 stars, based on 1 article reviews
d-ap5 nmda receptor antagonist - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris nmda receptor antagonist dl-ap5
Nmda Receptor Antagonist Dl Ap5, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nmda receptor antagonist dl-ap5/product/Tocris
Average 90 stars, based on 1 article reviews
nmda receptor antagonist dl-ap5 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris nmda receptor antagonist d-ap5
Nmda Receptor Antagonist D Ap5, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nmda receptor antagonist d-ap5/product/Tocris
Average 90 stars, based on 1 article reviews
nmda receptor antagonist d-ap5 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Tocris nmda receptor antagonist dl-2-amino-5-phosphonopentanoic acid ap5
Nmda Receptor Antagonist Dl 2 Amino 5 Phosphonopentanoic Acid Ap5, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nmda receptor antagonist dl-2-amino-5-phosphonopentanoic acid ap5/product/Tocris
Average 90 stars, based on 1 article reviews
nmda receptor antagonist dl-2-amino-5-phosphonopentanoic acid ap5 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

95
MedChemExpress nmda receptor antagonist ap 5
Nmda Receptor Antagonist Ap 5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nmda receptor antagonist ap 5/product/MedChemExpress
Average 95 stars, based on 1 article reviews
nmda receptor antagonist ap 5 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

96
Tocris nmda receptor antagonist d 2 amino 5 phosphonopentanoic acid
Drug (agonist/antagonists) conditions applied on electrophysiological recordings.
Nmda Receptor Antagonist D 2 Amino 5 Phosphonopentanoic Acid, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nmda receptor antagonist d 2 amino 5 phosphonopentanoic acid/product/Tocris
Average 96 stars, based on 1 article reviews
nmda receptor antagonist d 2 amino 5 phosphonopentanoic acid - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

Image Search Results


Drug (agonist/antagonists) conditions applied on electrophysiological recordings.

Journal: Frontiers in Neuroscience

Article Title: Analyzing the transient response dynamics of long-term depression in the mouse auditory cortex in vitro through multielectrode-array-based spatiotemporal recordings

doi: 10.3389/fnins.2024.1448365

Figure Lengend Snippet: Drug (agonist/antagonists) conditions applied on electrophysiological recordings.

Article Snippet: After stable baseline recording had been acquired for longer than 10 min by test stimulation before TS, we administered, at the end of each experiment, one of the following drugs: (i) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptor antagonist DNQX (Tocris Bioscience, Bristol, United Kingdom) at concentrations of 10 μM, (ii) NMDA receptor antagonist D-2-amino-5-phosphonopentanoic acid (D-AP5, Tocris Bioscience) at concentrations of 50 μM, (iii) metabotropic glutamate receptor 5 antagonist 6-methyl-2-(phenylethynyl)-pyridine hydrochloride (MPEP hydrochloride, Tocris Bioscience) at concentrations of 10 μM, (iv) GABA A receptor antagonist bicuculline methiodide (Tocris Bioscience) at concentrations of 5 μM, (v) GABA A receptor agonist muscimol (Toronto Research Chemicals, Toronto, CAN) at concentration of 5 μM, and (vi) GABA B receptor antagonist CGP 54626 hydrochloride (Tocris Bioscience) at 5 μM.

Techniques:

Current-driven responses in layer 4 of a brain slice under the glutamatergic receptor antagonist/agonist condition. (A) Under 10-μM D-AP5 application, LFP responses were recorded in layer 4 before and after TS. Three LFP responses are illustrated (i) before (black trace), (ii) 20 min (red trace), and (iii) 60 min after TS (blue trace) applied to layer 4 in (a) . The test stimuli were repetitively applied to layer 4. Time course of negative-going peak magnitude is illustrated during the whole recording period (70 min) in (b) . (B) Similarly, under 50-μM DNQX application, LFP responses were recorded in layer 4 before and after TS. Three LFP responses are illustrated (i) before (black trace), (ii) 20 min (red trace), and (iii) 60 min after TS (blue trace) applied to layer 4 in (a) . Time course of negative-going peak amplitudes is illustrated during the whole recording period (70 min) in (b) . (C) Under 50-μM MPEP application, LFP responses were recorded in layer 4 before and after TS. Three LFP responses are illustrated (i) before (black trace), (ii) 20 min (red trace), and (iii) 60 min after TS (blue trace) applied to layer 4 in (a) . The test stimuli were repetitively applied to layer 4. Time course of negative-going peak amplitudes is illustrated during the whole recording period (70 min) in (b) . TS was applied at time 0 min in the plot (indicated by a dashed line and an arrow). The timings of a test stimulus are indicated by the inverted triangles in (a) .

Journal: Frontiers in Neuroscience

Article Title: Analyzing the transient response dynamics of long-term depression in the mouse auditory cortex in vitro through multielectrode-array-based spatiotemporal recordings

doi: 10.3389/fnins.2024.1448365

Figure Lengend Snippet: Current-driven responses in layer 4 of a brain slice under the glutamatergic receptor antagonist/agonist condition. (A) Under 10-μM D-AP5 application, LFP responses were recorded in layer 4 before and after TS. Three LFP responses are illustrated (i) before (black trace), (ii) 20 min (red trace), and (iii) 60 min after TS (blue trace) applied to layer 4 in (a) . The test stimuli were repetitively applied to layer 4. Time course of negative-going peak magnitude is illustrated during the whole recording period (70 min) in (b) . (B) Similarly, under 50-μM DNQX application, LFP responses were recorded in layer 4 before and after TS. Three LFP responses are illustrated (i) before (black trace), (ii) 20 min (red trace), and (iii) 60 min after TS (blue trace) applied to layer 4 in (a) . Time course of negative-going peak amplitudes is illustrated during the whole recording period (70 min) in (b) . (C) Under 50-μM MPEP application, LFP responses were recorded in layer 4 before and after TS. Three LFP responses are illustrated (i) before (black trace), (ii) 20 min (red trace), and (iii) 60 min after TS (blue trace) applied to layer 4 in (a) . The test stimuli were repetitively applied to layer 4. Time course of negative-going peak amplitudes is illustrated during the whole recording period (70 min) in (b) . TS was applied at time 0 min in the plot (indicated by a dashed line and an arrow). The timings of a test stimulus are indicated by the inverted triangles in (a) .

Article Snippet: After stable baseline recording had been acquired for longer than 10 min by test stimulation before TS, we administered, at the end of each experiment, one of the following drugs: (i) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptor antagonist DNQX (Tocris Bioscience, Bristol, United Kingdom) at concentrations of 10 μM, (ii) NMDA receptor antagonist D-2-amino-5-phosphonopentanoic acid (D-AP5, Tocris Bioscience) at concentrations of 50 μM, (iii) metabotropic glutamate receptor 5 antagonist 6-methyl-2-(phenylethynyl)-pyridine hydrochloride (MPEP hydrochloride, Tocris Bioscience) at concentrations of 10 μM, (iv) GABA A receptor antagonist bicuculline methiodide (Tocris Bioscience) at concentrations of 5 μM, (v) GABA A receptor agonist muscimol (Toronto Research Chemicals, Toronto, CAN) at concentration of 5 μM, and (vi) GABA B receptor antagonist CGP 54626 hydrochloride (Tocris Bioscience) at 5 μM.

Techniques: Slice Preparation

Spatiotemporal properties of LTD around the tetanic and test stimulation electrodes under the conditions of NMDA receptor, non-NMDA receptor, and metabotropic glutamate receptor 3 antagonists. Ratio indices (RIs) of evoked responses at eight recording sites around the TS site during 60 min posterior to TS under the control and the antagonists (10-μM D-AP5, 50-μM DNQX, and 50-μM MPEP) conditions. (E) schematic representation of the tetanic and test stimulation sites at position (0, 0) and the eight recording sites (−1, 1), (−1, 0), (−1, −1), (0, 1), (0, −1), (1, 1), (1, 0), and (1, −1) in a two-dimensional array representation for (A–D,F–I) , respectively. Each of the inter-electrode distances (IEDs) was 150 μm. In the abscissa of each bar graph, time in minutes represents the time points after TS with a 10-min step. We used an ANOVA for multiple comparisons followed by a post-hoc Steel-Dwass test: control ( n = 7), D-AP5 ( n = 6), DNQX ( n = 7), and MPEP ( n = 6). * and ** represent p < 0.05 and p < 0.01, respectively.

Journal: Frontiers in Neuroscience

Article Title: Analyzing the transient response dynamics of long-term depression in the mouse auditory cortex in vitro through multielectrode-array-based spatiotemporal recordings

doi: 10.3389/fnins.2024.1448365

Figure Lengend Snippet: Spatiotemporal properties of LTD around the tetanic and test stimulation electrodes under the conditions of NMDA receptor, non-NMDA receptor, and metabotropic glutamate receptor 3 antagonists. Ratio indices (RIs) of evoked responses at eight recording sites around the TS site during 60 min posterior to TS under the control and the antagonists (10-μM D-AP5, 50-μM DNQX, and 50-μM MPEP) conditions. (E) schematic representation of the tetanic and test stimulation sites at position (0, 0) and the eight recording sites (−1, 1), (−1, 0), (−1, −1), (0, 1), (0, −1), (1, 1), (1, 0), and (1, −1) in a two-dimensional array representation for (A–D,F–I) , respectively. Each of the inter-electrode distances (IEDs) was 150 μm. In the abscissa of each bar graph, time in minutes represents the time points after TS with a 10-min step. We used an ANOVA for multiple comparisons followed by a post-hoc Steel-Dwass test: control ( n = 7), D-AP5 ( n = 6), DNQX ( n = 7), and MPEP ( n = 6). * and ** represent p < 0.05 and p < 0.01, respectively.

Article Snippet: After stable baseline recording had been acquired for longer than 10 min by test stimulation before TS, we administered, at the end of each experiment, one of the following drugs: (i) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptor antagonist DNQX (Tocris Bioscience, Bristol, United Kingdom) at concentrations of 10 μM, (ii) NMDA receptor antagonist D-2-amino-5-phosphonopentanoic acid (D-AP5, Tocris Bioscience) at concentrations of 50 μM, (iii) metabotropic glutamate receptor 5 antagonist 6-methyl-2-(phenylethynyl)-pyridine hydrochloride (MPEP hydrochloride, Tocris Bioscience) at concentrations of 10 μM, (iv) GABA A receptor antagonist bicuculline methiodide (Tocris Bioscience) at concentrations of 5 μM, (v) GABA A receptor agonist muscimol (Toronto Research Chemicals, Toronto, CAN) at concentration of 5 μM, and (vi) GABA B receptor antagonist CGP 54626 hydrochloride (Tocris Bioscience) at 5 μM.

Techniques: Control

Numbers of monostable or bistable potentials in the total eight electrode sites.

Journal: Frontiers in Neuroscience

Article Title: Analyzing the transient response dynamics of long-term depression in the mouse auditory cortex in vitro through multielectrode-array-based spatiotemporal recordings

doi: 10.3389/fnins.2024.1448365

Figure Lengend Snippet: Numbers of monostable or bistable potentials in the total eight electrode sites.

Article Snippet: After stable baseline recording had been acquired for longer than 10 min by test stimulation before TS, we administered, at the end of each experiment, one of the following drugs: (i) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptor antagonist DNQX (Tocris Bioscience, Bristol, United Kingdom) at concentrations of 10 μM, (ii) NMDA receptor antagonist D-2-amino-5-phosphonopentanoic acid (D-AP5, Tocris Bioscience) at concentrations of 50 μM, (iii) metabotropic glutamate receptor 5 antagonist 6-methyl-2-(phenylethynyl)-pyridine hydrochloride (MPEP hydrochloride, Tocris Bioscience) at concentrations of 10 μM, (iv) GABA A receptor antagonist bicuculline methiodide (Tocris Bioscience) at concentrations of 5 μM, (v) GABA A receptor agonist muscimol (Toronto Research Chemicals, Toronto, CAN) at concentration of 5 μM, and (vi) GABA B receptor antagonist CGP 54626 hydrochloride (Tocris Bioscience) at 5 μM.

Techniques: Control

Trajectories of the synaptic efficacy models with the estimated coefficients under the different drug conditions. (A) Trajectories of the glutamate group. (B) Trajectories of the GABA group. (C) Distribution of data points on the first and second principal component space (PC 1 vs. PC 2 ). The dashed line indicates the boundary between two major groups (i.e., glutamate vs. GABA groups): the glutamatergic group (i.e., D-AP5, MPEP, and DNQX) and GABAergic group (i.e., bicuculline, CGP, and muscimol). (D) The angles of the paired centroid vectors among all groups are illustrated.

Journal: Frontiers in Neuroscience

Article Title: Analyzing the transient response dynamics of long-term depression in the mouse auditory cortex in vitro through multielectrode-array-based spatiotemporal recordings

doi: 10.3389/fnins.2024.1448365

Figure Lengend Snippet: Trajectories of the synaptic efficacy models with the estimated coefficients under the different drug conditions. (A) Trajectories of the glutamate group. (B) Trajectories of the GABA group. (C) Distribution of data points on the first and second principal component space (PC 1 vs. PC 2 ). The dashed line indicates the boundary between two major groups (i.e., glutamate vs. GABA groups): the glutamatergic group (i.e., D-AP5, MPEP, and DNQX) and GABAergic group (i.e., bicuculline, CGP, and muscimol). (D) The angles of the paired centroid vectors among all groups are illustrated.

Article Snippet: After stable baseline recording had been acquired for longer than 10 min by test stimulation before TS, we administered, at the end of each experiment, one of the following drugs: (i) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptor antagonist DNQX (Tocris Bioscience, Bristol, United Kingdom) at concentrations of 10 μM, (ii) NMDA receptor antagonist D-2-amino-5-phosphonopentanoic acid (D-AP5, Tocris Bioscience) at concentrations of 50 μM, (iii) metabotropic glutamate receptor 5 antagonist 6-methyl-2-(phenylethynyl)-pyridine hydrochloride (MPEP hydrochloride, Tocris Bioscience) at concentrations of 10 μM, (iv) GABA A receptor antagonist bicuculline methiodide (Tocris Bioscience) at concentrations of 5 μM, (v) GABA A receptor agonist muscimol (Toronto Research Chemicals, Toronto, CAN) at concentration of 5 μM, and (vi) GABA B receptor antagonist CGP 54626 hydrochloride (Tocris Bioscience) at 5 μM.

Techniques:

Potential functions concerning the synaptic efficacy models obtained from recorded RI data sets. (A) D-AP5 vs. control conditions. (B) DNQX. (C) MPEP. (D) CGP. (E) Bicuculline. (F) Muscimol. The potential functions of the control group are also superimposed on each plot. Furthermore, in each plot, eight potential functions were individually obtained from the eight nearest electrode sites around the TS site, suggesting the spatial variability among the recording sites (electrodes).

Journal: Frontiers in Neuroscience

Article Title: Analyzing the transient response dynamics of long-term depression in the mouse auditory cortex in vitro through multielectrode-array-based spatiotemporal recordings

doi: 10.3389/fnins.2024.1448365

Figure Lengend Snippet: Potential functions concerning the synaptic efficacy models obtained from recorded RI data sets. (A) D-AP5 vs. control conditions. (B) DNQX. (C) MPEP. (D) CGP. (E) Bicuculline. (F) Muscimol. The potential functions of the control group are also superimposed on each plot. Furthermore, in each plot, eight potential functions were individually obtained from the eight nearest electrode sites around the TS site, suggesting the spatial variability among the recording sites (electrodes).

Article Snippet: After stable baseline recording had been acquired for longer than 10 min by test stimulation before TS, we administered, at the end of each experiment, one of the following drugs: (i) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptor antagonist DNQX (Tocris Bioscience, Bristol, United Kingdom) at concentrations of 10 μM, (ii) NMDA receptor antagonist D-2-amino-5-phosphonopentanoic acid (D-AP5, Tocris Bioscience) at concentrations of 50 μM, (iii) metabotropic glutamate receptor 5 antagonist 6-methyl-2-(phenylethynyl)-pyridine hydrochloride (MPEP hydrochloride, Tocris Bioscience) at concentrations of 10 μM, (iv) GABA A receptor antagonist bicuculline methiodide (Tocris Bioscience) at concentrations of 5 μM, (v) GABA A receptor agonist muscimol (Toronto Research Chemicals, Toronto, CAN) at concentration of 5 μM, and (vi) GABA B receptor antagonist CGP 54626 hydrochloride (Tocris Bioscience) at 5 μM.

Techniques: Control